57.00
+0.1(+0.18%)
Currency In TWD
Sector
Healthcare
Industry
Biotechnology
Employees
139
First IPO Date
August 13, 2015
| Name | Title | Pay | Year Born |
| Mr. Stephen Lam | Chief Executive Officer & Director | 0 | N/A |
| Dr. Allen Y. Chao Ph.D. | Founder & Honorary Chairman | 111,000 | 1946 |
| Ms. Angela Luan | Chief Financial Officer & Corporate Governance Officer | 0 | N/A |
| May Hung | Chief Internal Auditor | 0 | N/A |
| Mr. James Williamson | Accounting Officer | 0 | N/A |
| Hsun-Chiang Hsieh | Secretary | 0 | N/A |
| Linda Grillo | Director of Sales & Marketing | 0 | N/A |
| Val Chen | Vice President of Finance, Director of Operations. Management & Corporate Governance Officer | 0 | N/A |
| Mr. Zheng Xia | Chief Technology Officer | 0 | N/A |
| Mr. Marc Goemans | Chief Commercial Officer | 0 | N/A |
Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.